Thermo Fisher’s clinical research subsidiary, PPD, invests $59 million in sample management and testing capacity for vaccines and cell and gene therapy products with its expansion of laboratory operations in Kentucky.
Thermo Fisher Scientific’s clinical service unit PPD has won some “very large” customers since becoming part of the broader group in a mega-merger, according to CEO Marc Casper.
Changing to DCT is more than merely flipping a switch; two leaders from the Thermo Fisher Scientific business offer advice for implementing the format.
Medable has added Cognizant to its Medable Partner Network, designed to help companies launch their clinical trials more quickly and run them more efficiently.
The past several days have seen a relatively large number of industry acqusitions, with Lilly, Phillip Morris, WCG, CTI and others making notable buys.
The chairman, president and CEO of Thermo Fisher says the acquisition stands to benefit clinical trial and drug development clients in a long list of ways.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The two companies have partnered to develop a systemic erythematosus assessment review to streamline clinical trials centered on the autoimmune disease.
The CRO will receive funding to fuel a five-year Research Project Award, with the goal to design and conduct research of potential PTSD treatment options.
This month's spotlight on new hires, promotions and company acquisitions involves Elligo Health Research, PPD, Pfizer, Covance and other industry firms.
Arsenal has acquired BresMed to form a value demonstration company intended to support biopharmaceutical clients through strategy, evidence and communication tools.
PPD adds clinical research unit with ‘strong’ recruiting track record to its portfolio, enabling studies on patient populations ‘more reflective’ of the products’ end-users.
PPD is expanding its immunochemistry and biomarker space by 8,000 square feet, the addition of which will also support a dedicated team for one of the company’s global biopharmaceutical clients.
The acquisition of Bioclinica’s clinical research site business extends PPD’s trial enrollment business to five continents, 20 countries, and more than 180 research sites.
Harbour BioMed has selected PPD as its preferred CRO partner as part of a strategic collaboration to develop novel oncology and immunology therapeutics.
To further support Asia-Pacific oncology trials, NeoGenomics opens new Singapore-based pharma services laboratory in the same building as PPD Laboratories’ central lab.
PPD’s patient enrollment business expands access to cancer patients treated in the community setting as part of a new collaboration with a hospital and outpatient center network.
PPD’s patient access business unit AES will support clinical trial enrollment of participants in the Synexus HealthyMinds Registry, which aims to register 30,000 adults for a five-year study.
PPD’s Evidera business unit is set to acquire Medimix International, a global technology company with a real-world evidence service offering that includes access to patient-level data, data analytics, and visualization capabilities.
The industry group recently announced its first technology standard, which addresses operational data exchange in an aim to improve information sharing between sponsors and CROs.
PPD is adding nearly 6,000 square feet of new lab space – and about 20 employees – dedicated to gene and cell therapy analytical testing at its site in Athlone, Ireland.
CROs this month have made significant new hires with WCG adding eight to its scientific leadership team, PPD hiring four, and BioIVT filling its new-created role of CCO.
Also, making the move from Bioclinica, David Kiger has been named...
Patient centricity quite plainly means to put the patient at the “front and center,” explained Rhonda Henry, vice president, site collaborations and patient centricity, PPD – though many remain confused on how to be “patient centric.”
PPD has expanded its central lab technology capabilities with the launch of a new client portal and a companion application for its Preclarus investigator site portal.
Synexus is looking to register 30,000 adults for a five-year study with the goal of identifying potential prevention methods and possible treatments for Alzheimer’s disease and other dementias.
Pharmaceutical Product Development (PPD) is set to acquire evidence-based solutions provider Evidera, as the need for real-world data continues to grow.
CROs Pharmaceutical Product Development (PPD) and ERT on Tuesday announced a strategic partnership to deliver ERT’s patient safety and efficacy endpoint data collection tools to help biopharma clients conduct clinical trials in a more efficient and cost-effective...
A US FDA investigation of CRO PPD did not uncover any violations that might prompt a Form 483 for its work related to Bristol-Myers Squibb’s approved drug, Eliquis.
PPD’s acquisition of Merck’s vaccine testing laboratory will give it a geographic location from which it can compete for business with its “number one competitor”, which is well established in the north east of the US.
Contract research organisation PPD has boosted its compound partnering programme with the purchase of dermatology specialist Magen BioSciences, and divested its presclinical research subsidiary Pedmont Research Centre.
Pharmaceutical Product Development of the US is expecting to post a 12 per cent hike in revenues in 2009, helped by the recent opening of offices in Ireland and Singapore and new deals with Merck & Co.
Pharmaceutical Product Development (PPD) reported a bumper set of second quarter figures, well ahead of analysts expectations, but saw its share price take a dip anyway.
Pharmaceutical Products Development (PPD) has announced it is
moving into Russia, along with the news of positive trial results
for its statin, although profits dipped again during the fourth
quarter of 2007 as its R&D bill mounts.
Pharmaceutical Product Development (PPD) has initiated central
laboratory services in China in response to the country's budding
clinical trials scene.
PPD's decision to in-license an investigational compound is proving
to be a drag on its bottom line as the firm continues to seek a
development partner for the drug.
As global contract research spending remains robust, business is
booming for Pharmaceutical Product Development (PPD) as the US firm
reported a surge in sales, profits and new business for its second
quarter 2006.
PPD managed a 42 per cent jump in pre-tax profit to the tune of
$63.8m (€50.1m) in the first quarter, fuelled by a strong growth in
new clinical trials business and helped by a milestone payment in
the discovery sciences segment.